International Biotechnology, Chemical Engineering and Life Science Conference

July 25-27, 2017 Okinawa, Japan

Keynote Speech

Microfluidic nanotechnology: what does it do for you?


Paul C.H. Li Ph.D.

Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, CANADA

Summary of Keynote Speech

Multidrug resistance (MDR) is one of the major obstacles in cancer drug delivery. MDR may be overcome by using inhibitors. We employed the microfluidic single cell biochip (SCB) to measure patients’ cancer cells for their drug uptake, which would be enhanced by using MDR inhibitors. We also use polymeric nanoparticles to help deliver drugs to treat the cancer cells. Drug uptake enhanced by MDR inhibitors may indicate a good prognosis for leukemia patient treatment.

Mutations in certain cancer genes such as KRAS in patients will suggest poor cancer prognosis due to treatment failure. The fast and high throughput nucleic acid assay has been conducted in centrifugal microfluidic biochip (CMB). This assay is used for detection of the occurrence in KRAS gene mutation in bowel cancer patients. Gold nanoparticles have been employed in enhancing the detection specificity, discriminating the wild-type versus mutated KRAS gene in patients’ DNA samples.

Microfluidic nanotechnology combines the use of the microfluidic chip with nanoparticles for in-vitro diagnosis and health care applications.

About the Speaker

Dr. Paul Li obtained his Ph.D degree in analytical chemistry at the University of Toronto in 1995. Then, he developed the microfluidic lab-on-a-chip at the University of Alberta during his postdoctoral work. Dr. Li became assistant professor at City University of Hong Kong in 1996. He then joined Simon Fraser University in 1999, and was promoted to full professor in 2010.

Dr. Li is interested in integrating microfluidics for single-cell analysis in order to study the transport kinetics of chemical compounds (from herbs) on individual cancer cells. This study is particularly useful for studying multidrug resistant cancer cells, leading to potential applications in chemotherapy.  He is also interested to combine microfluidics with the nucleic acid bioarray for detection of low volume and low concentration of fungal pathogenic DNA, KRAS cancer gene DNA, and influenza viral RNA. To enhance specificity, he uses nanoparticles and nanostructured materials in the microfluidic systems. He has published Fundamentals of Lab on a Chip for Biological Analysis and Discovery in 2010, and Microarray Technology: Methods and Applications in 2016. He is associate editor of Canadian Journal of Pure and Applied Sciences, and sits on the editorial boards of Journal of Proteomics and Genomics and Hong Kong Pharmaceutical Journal. He has been visiting professors at the University of Mainz (Germany), Queenlsand Institute for Medical Research (Australia), National Cancer Institute (USA), Griffith University (Australia), and Australian Prostate Cancer Centre. Dr. Li is the inventor of 4 granted patents and 5 pending patents, and he is the founder and vice president of ZellChip Technologies Inc. specializing in microfluidic-based instruments for life science applications.

Venue- Okinawa Convention Center

Address: 4-3-1 Mashiki, Ginowan City Okinawa 901-2224, Japan

Okinawa Convention Center (OCC) located in the seaside area, Ginowan city, on the west coast of central Okinawa island.